Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
17 hedge funds and large institutions have $11.4M invested in Bellerophon Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
30% less capital invested
Capital invested by funds: $16.3M → $11.4M (-$4.86M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$37.8K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$29.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$23.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$22.1K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$246K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$110K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$78K |
| 4 |
LPL Financial
San Diego,
California
|
-$23.1K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$23K |
BLPH Hedge Fund Activity: Q2 2016 in Review
17 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2016, worth a combined $11.4M — down 30% from $16.3M a quarter earlier.
Fund positioning in BLPH was balanced in Q2 2016: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $37.8K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $246K sold.
- 17 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $11.4M of Bellerophon Therapeutics, Inc. stock for Q2 2016, down 30% quarter-over-quarter.
- 5 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2016 and 5 closed out, a net change of 0 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2016 was Renaissance Technologies, an estimated $37.8K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2016 was Bridgeway Capital Management, an estimated $246K sold.
Based on aggregated 13F filings for Q2 2016.